Navigation Links
New data on islet autoantibodies in young children defines early type 1 diabetes development

New York, NY, June 19, 2013 A decade-long JDRF-funded study led by the Institute of Diabetes Research in Helmholtz Zentrum Mnchen, Germany, is providing a deeper understanding of the link between autoantibodies and the risk of developing type 1 diabetes (T1D), highlighting the importance of pre-diabetes research into possible preventions for the disease. The study, "Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children," was published today in The Journal of the American Medical Association.

Researchers in Colorado (DAISY study), Finland (DIPP study), and Germany (BABYDIAB) followed children from infancy until as old as three years old, to determine the presence of islet autoantibodiesmarkers that indicate the activation of the autoimmune attack on insulin-producing beta cells in the pancreas. T1D occurs when these beta cells are destroyed, rendering people with the disease unable to produce their own insulin. The new findings reveal that nearly 70 percent of the 585 young children studied (in all three countries) who had two or more autoantibodies developed T1D within 10 years, with 84 percent developing T1D in 15 years. The study also revealed that 14.5 percent of the 474 children with a single islet autoantibody developed T1D within 10 years, and that progression of the disease was faster for those who showed the presence of antibodies at younger than three years old. The risk for children without autoantibodies was only 0.4 percent by age 15 years.

"This is the first true estimate from when we think the process of type 1 diabetes starts, and the largest dataset that exists, with over 13,000 children followed from birth and over 1,000 children who developed antibodies," said Anette-Gabriele Ziegler, M.D., director of the Institute of Diabetes Research, who led the study in Germany. "I believe that this sort of data should make us consider whether the status of confirmed multiple islet autoantibodies be used in the staging of type 1 diabetes. This will allow more consideration for intervention necessary to stop or delay progression to the full and irreversible metabolic disease."

"These findings will help us to better identify children who are at the highest risk for developing type 1 diabetes, and allow scientists to focus prevention efforts on groups who are most likely to become insulin dependent," said Jessica Dunne, senior scientist at JDRF. "Prevention of type 1 diabetes is a priority for JDRF, and it is work like this that sets the stage for our efforts."

As a next step, JDRF and its partners are advancing research to develop potential vaccines for T1D and to test compounds that may prevent onset of T1D in those at risk for the disease. A critical part of that effort is a study funded by the National Institutes of Health (NIH) through the Special Diabetes Program (SDP) called TEDDY (The Environmental Determinants of Diabetes in the Young), which is testing whether factors such as antibiotics, viruses, gut microbes, cows' milk, deficiency of vitamin D, omega-3s, or other environmental causes are triggers for the onset of the T1D in those at risk. JDRF is a leading advocate for the renewal of the SDP in Congress, which funds $150 million a year in T1D research through the NIH.


Contact: Tara Wilcox-Ghanoonparvar

Related biology news :

1. Cell Transplantation reports islet cell advancement increases impact on transplantation
2. Some factors that impact islet transplantation explored in Cell Transplantation papers
3. Some factors that impact islet transplantation explored in Cell Transplantation papers
4. Flu vaccines aimed at younger populations could break annual transmission cycle
5. Peihua Jiang receives Ajinomoto Award for Young Investigators in Gustation from AChemS
6. Birds find ways to avoid raising cuckoos young
7. Teen mentors inspire healthier choices in younger children
8. Risk management in fish: How cichlids prevent their young from being eaten
9. Fruit flies force their young to drink alcohol -- for their own good
10. Young malaria parasites refuse to take their medicine, may explain emerging drug resistance
11. Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
Post Your Comments:
(Date:10/12/2015)... , Oct. 12, 2015 ... end-to-end authentication infrastructure company, will introduce its ... captures four prints simultaneously, providing an unprecedented ... well as discuss the new biometric standard ... highlight how enterprises from financial services to ...
(Date:10/8/2015)... , 8. Oktober 2015 Die ... tätiges Unternehmen des Bereiches Tracking, hat heute ... der Gefängnisbehörde Virginias (Department of Corrections – ... Überwachungsdienste für alle Strafen geliefert werden, die ... , Präsident für den Amerikanischen Kontinent der ...
(Date:10/6/2015)... , Oct. 6, 2015  Maverix Biomics, ... announced enhancements to its software portfolio with the ... kit for differential expression in eukaryotes. The software ... is a cloud-based genomic analysis solution that leverages ... discovery from next-generation sequencing efforts. Garry ...
Breaking Biology News(10 mins):
(Date:10/12/2015)... , 12 de octubre de 2015 El ... llegó a un récord en el congreso con su ... de la International Plasma Awareness Week (IPAW), que se ... está patrocinada por la Plasma Protein Therapeutics Association ... , Aumentar la concienciación mundial acerca ...
(Date:10/12/2015)... Belgium , Oct. 12, 2015 VolitionRx ... from a completed clinical study of its NuQ ® ... in the online issue of Clinical Epigenetics , the ... was conducted in collaboration with Lund ... Roland Andersson , MD, PhD, Professor of Surgery and Vice-Dean, ...
(Date:10/10/2015)... le 10 octobre 2015 Le 8 octobre, l,honorable ... le Registre du Congrès sa déclaration de soutien ... sensibilisation autour du plasma (IPAW), qui se tiendra ... la Plasma Protein Therapeutics Association (PPTA) ... , Sensibiliser l,opinion publique mondiale autour ...
(Date:10/9/2015)... Oct. 9, 2015  DePuy Synthes Trauma* announced today ... Q-PACK ®  Technology**, the only pre-hydrated demineralized cancellous ... procedures (foot and ankle, hand and wrist), including fusion, ... here at the 2015 Orthopaedic Trauma Association (OTA) Annual ... scaffold for new bone growth) and osteoinductive 2,3 ...
Breaking Biology Technology: